NeuExcell Therapeutics‘ investigational gene therapy, NXL-004, showed a potential survival benefit in a small group of people with recurrent malignant glioma in an…

Cellxlife signed a licensing agreement for a cell-based vaccine from Mayo Clinic that aims to teach the body’s immune system to recognize and…

Tecvayli (teclistamab) extended survival and kept disease under control longer than standard treatments in patients with relapsed or refractory multiple myeloma, meaning the…